CD4 and CD8: Modulators of T-cell receptor recognition of antigen and of immune responses?

Current Opinion in Immunology

Volumn 10, Issue 1, 1998, Pages 82-87

  Zamoyska, Rose ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; CELL DIFFERENTIATION; CLONAL ANERGY; IMMUNE RESPONSE; LIGAND BINDING; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0032006123     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80036-8     Document Type: Article

References (59)

1. Swain S. T cell subsets and the recognition of MHC class. Immunol Rev. 74:1983;129-142.
2. Cammarota G, Schierle A, Takacs B, Doran D, Knorr R, Bannworth W, Guardiola J, Sinigaglia F. Identification of a CD4 binding site on the b2 domain of HLA-DR molecules. Nature. 356:1992;799-801.
3. König R, Huang L-Y, Germain R. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature. 356:1992;796-798.
4. Norment AM, Salter RD, Parham P, Engelhard VH, Littman VH. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature. 336:1988;79-81.
5. Salter RD, Benjamin H, Wesley PK, Buxton SE, Garrett TPJ, Clayberger C, Krensky AM, Norment AM, Littman DR, Parham P. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2. Nature. 345:1990;41-46.
6. lck. Cell. 55:1988;301-308.
7. Rudd C, Trevillyan J, Dasgupta J, Wong L, Schlossman S. The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc. Natl Acad Sci USA. 85:1988;5190-5194.
8. Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell. 70:1992;585.
9. Wange R, Samelson L. Complex complexes: signaling at the TCR. of special interest Immunity. 5:1996;197-205 A recent review of the molecules involved in proximal tyrosine phosphorylation events which accompany TCR triggering.
10. Owens T, Fazekas de St Groth B, Miller J. Coaggregation of the T cell receptor with CD4 and other T cell surface molecules enhances T cell activation. Proc Natl Acad Sci USA. 84:1987;9209-9213.
11. Boyce NW, Jönsson JI, Emmrich F, Eichmann K. Heterologous cross-linking of Lyt-2 (CD8) to the αβ-T cell rceptor is more effective in T cell activation than homologous αβT cell receptor cross-linking. J Immunol. 141:1988;2882-2888.
12. Jonsson J-I, Boyce NW, Eichmann K. Immunoregulation through CD8 (Ly-2): state of aggregation with the αβ/CD3 T cell receptor controls interleukin 2-dependent T cell growth. Eur J Immunol. 19:1989;253-260.
13. Janeway CJ. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol. 10:1992;645-674.
14. Sloan-Lancaster J, Allen P. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. of special interest Annu Rev Immunol. 14:1996;1-27 A comprehensive review of altered peptide ligands, encompassing an overview of current hypotheses of how they exert their effects.
15. Shaw AS, Dustin ML. Making the T cell receptor go the distance: a topological view of T cell activation. of special interest Immunity. 6:1997;361-369 A refreshing look at T-cell activation which discusses how the physical attributes (size, glycosylation and charge) of various receptors on T cells may affect their interactions with each other and their ligands, and pays particular attention to the different classes of receptors which participate in T-cell activation.
16. Ryu S-E, Kwong P, Trunch A, Porter T, Arthos J, Rosenberg M, Dai X, Xuong N, Axel R, Sweet R, Hendrickson W. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature. 348:1990;419-425.
17. Wang J, Yan Y, Garrett T, Liu J, Rodgers D, Garlick R, Tarr G, Husain Y, Reinherz E, Harrison S. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 348:1990;411-418.
18. Brady RL, Dodson EJ, Dodson GG, Lange G, Davis SJ, Williams AF, Barclay AN. Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains. Science. 260:1993;83-979.
19. Wu H, Kwong PD, Hendrickson WA. Dimeric association and segmental variability in the structure of human CD4. of special interest Nature. 387:1997;527-530 The solution of the crystal structure of the intact CD4 is described, indicating the presence of dimers at high protein concentration.
20. Reich Z, Boniface JJ, Lyons DS, Borochov N, Wachtel EJ, Davis MM. Ligand-specific oligomerization of T-cell receptor molecules. of outstanding interest Nature. 387:1997;617-620 This paper describes how TCRs have the potential to oligomerise in a concentration-dependent manner when binding to antigenic MHC/peptide complexes, suggesting that T cell signalling may indeed require TCR multimerisation.
21. Vignali DA, Carson RT, Chang B, Mittler BS, Strominger JL. The two membrane proximal domains of CD4 interact with the T cell receptor. of special interest J Exp Med. 183:1996;2097-2107 Chimaeric mouse CD4 molecules, in which the membrane proximal domains (D3 and D4) were substituted for a variety of other structures, were analysed for their abilities to act as co-receptors. Most interesting were hybrids containing mouse D1 and D2 and human D3 and D4 domains, which not only failed to restore T-cell signalling but acted as a dominant negative interfering with wild-type CD4 function.
22. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol. 44:1989;265-311.
23. Leahy DJ, Axel R, Hendrickson WA. Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 Å resolution. Cell. 68:1992;1145-1162.
24. 2-microglobulin as sites of interaction. Interestingly, the CD8 homodimer is shown to interact asymmetrically with class I, with only one of the polypeptides making most of the contacts.
25. Snow PM, Terhorst C. The T8 antigen is a multimeric complex of two distinct subunits on human thymocytes but consists of homomultimeric forms on peripheral blood T lymphocytes. J Cell Biol. 258:1983;14675-14681.
26. Crooks M, Littman D. Disruption of T lymphocyte positve and negative selection in mice lacking the CD8β chain. Immunity. 1:1994;277-286.
27. + T cells in CD8β genetargetted mice. J Exp Med. 180:1994;959-967.
28. Yoko Irie H, Ravichandran KS, Burakoff SJ. CD8 beta chain influences CD8 alpha chain-associated Lck kinase activity. J Exp Med. 181:1995;1267-1273.
29. Garcia KC, Scott CA, Brunmark A, Carbone FR, Peterson PA, Wilson IA, Teyton L. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. of outstanding interest Nature. 384:1996;577-581 Surface plasmon resonance was used to measure the binding kinetics of CD8αα homodimers and αβ heterodimers to class I MHC. The binding kinetics of the two forms were found to be similar, except that the heterodimer had a slightly faster 'on' rate. The CD8 heterodimer was found to have a significant influence on the interaction between TCR and MHC-peptide molecules, by stabilising the complex formed between them.
30. Renard V, Romero P, Vivier E, Malissen B, Luescher I. CD8β increases CD8 co-receptor function and participation in TCR-ligand binding. of outstanding interest J Exp Med. 184:1996;2439-2444 This paper describes a comparison between CD8αα homodimers and αβ heterodimers in restoring the response of a T cell hybridoma. CD8αβ heterodimers were found to be more efficient in promoting the response to antigen and increase T-cell receptor (TCR) - ligand binding more efficiently than CD8αα homodimers.
31. O'Rourke A, Mescher M. The roles of CD8 in cytotoxic T lymphocyte function. Immunol Today. 14:1993;183-188.
32. Luescher IF, Vivier E, Layer A, Mahiou J, Godeau F, Malissen B, Romero P. CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature. 373:1995;353-356.
33. O'Rourke A, Apgar J, Kane K, Martz K, Mescher M. Cytoskeletal function in CD8- and T cell receptor-mediated interaction of cytotoxic T lymphocytes with class I protein. J Exp Med. 173:1991;241-249.
34. Rahemtulla A, Fung-Leung W, Schilham S, Kundig T, Sambhara S, Narendran A, Arabian A, Wakeham A, Paige C, Zinkernagel R, et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 353:1991;180-184.
35. Fung-Leung W-P, Schillham M, Rahemtulla A, Kündig T, Vollenweider M, Potter J, van Ewijk M, Mak T. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell. 65:1991;443-449.
36. lck association. Nature. 364:1993;729-732.
37. + T lymphocytes. Eur J Immunol. 23:1993;2834-2840.
38. wild-type thymocytes. These data show that the CD8 molecule does not provide an obligatory function for differentiation of class I-restricted T cells, but suggests CD8 alters the threshold for positive and negative selection.
39. of outstanding interest Sebzda E, Choi M, Fung-Leung WP, Mak TW, Ohashi PS. Peptide-induced positive selection of TCR transgenic thymocytes in a co-receptor-independent manner. of special interest Immunity. 6:1997;643-653 A contemporaneous study to [38] reaching similar conclusions for a second class I-restricted transgenic T-cell receptor.
40. Blok R, Marguiles D, Pease L, Ribaudo R, Schneck J, McCluskey J. CD8 expression alters the fine specificity of an alloreactive MHC class I-specific T hybridoma. Int Immunol. 4:1992;455-466.
41. Miceli M, Parnes J. Role of CD4 and CD8 in T cell activation and differentiation. Adv Immunol. 53:1993;59-122.
42. Jameson SC, Bevan MJ. T cell receptor antagonists and partial agonists. Immunity. 2:1995;1-11.
43. Renard V, Delon J, Luescher IF, Malissen B, Vivier E, Trautmann A. The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist. Eur J Immunol. 26:1996;2999-3007.
44. Mannie M, Rosser J, White G. Autologous rat myelin basic protein is a partial agonist that is converted into a full antagonist upon blockade of CD4. J Immunol. 154:1995;2642-2654.
45. Vidal K, Hsu BL, Williams CB, Allen PM. Endogenous altered peptide ligands can affect peripheral T cell responses. J Exp Med. 183:1996;1311-1321.
46. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. of outstanding interest J Exp Med. 185:1997;219-229 This is a functional and biochemical analysis of the consequence of limiting the association of CD4 with the T-cell receptor (TCR) upon ligand engagement. The effect of preventing the involvement of CD4 was to alter the response to an individual peptide from that described for agonist peptides to that described for antagonist peptides. This study provides biochemical evidence for the participation of the co-receptor in a qualitative manner in the TCR signal transduction cascade.
47. Cobbold SP, Qin S, Leong LY, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev. 129:1992;165-201.
48. Pearson TC, Madsen JC, Larsen CP, Morris PJ, Wood KJ. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation. 54:1992;475-483.
49. Shizuru JA, Alters SE, Fathman SG. Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult. Immunol Rev. 129:1992;105-130.
50. Smith JA, Yun Tso J, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. of outstanding interest J Exp Med. 185:1997;1413-1422 This study shows that engaging the TCR with non-stimulatory anti-CD3 antibodies, which fail to involve the co-receptors, induces anergy in the targeted T-cell population. These results have important implications for therapeutic modulation of T-cell responses in vivo.
51. o cells were found to differentiate only into the Th1 subset.
52. Kwan Lim G, Ong T, Aosai F, Stauss H, Zamoyska R. Is CD8 dependence a true reflection of TCR affinity for antigen. Int Immunol. 5:1993;1219-1228.
53. Auphan N, Curnow J, Guimezanes A, Langlet C, Malissen B, Mellor A, Schmitt-Verhulst A-M. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice. Eur Immunol. 24:1994;1572-1577.
54. Yelon D, Spain LM, Lim K, Berg LJ. Alterations in CD4 dependence accompany T cell development and differentiation. Int Immunol. 8:1996;1077-1090.
55. Anel A, Martinez Lorenzo MJ, Schmitt Verhulst AM, Boyer C. Influence on CD8 of TCR/CD3-generated signals in CTL clones and CTL precursor cells. of special interest J Immunol. 158:1997;19-28 Biochemical evaluation of the differences in signalling between a CD8-independent and a CD8-dependent T-cell receptors (TCRs) expressed in cytotoxic T lymphocytes (CTL)-precursor cells and clones. The data indicate that the response of the former of stronger and more sustained than the latter, even when anti-CD3 antibodies are used as the stimulus, indicating these differences in signalling potential are acquired during development.
56. Housset D, Mazza G, Gregoire C, Piras C, Malissen B, Fontecilla-Camps JC. The three-dimensional structure of a T-cell antigen receptor VaVb heterodimer reveals a novel arrangement of the Vb domain. of outstanding interest EMBO J. 16:1997;4205-4216 The crystal structure of a CD8-dependent TCR which differs from other published TCR structures in the nature of its CDR3β loop. This TCR is predicted to have to undergo a structural change in order to bind its MHC - peptide ligand, and it will be interesting to determine whether this requirement for conformational modification will relate to its CD8 dependency.
57. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 274:1996;209-219.
58. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 384:1996;134-141.
59. lck. Eur J Immunol. 28:1998;. in press.